Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.

NCT Number	NCT07480382
Lead Sponsor	Hong Wu
Conditions	Initially Unresectable Hepatocellular Carcinoma
Enrollment	30 participants
Start Date	2026-04-01
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-18